B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Top Cited Papers
- 15 December 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 20 (3), 179-199
- https://doi.org/10.1038/s41573-020-00092-2
Abstract
In the past 15 years, B cells have been rediscovered to be not merely bystanders but rather active participants in autoimmune aetiology. This has been fuelled in part by the clinical success of B cell depletion therapies (BCDTs). Originally conceived as a method of eliminating cancerous B cells, BCDTs such as those targeting CD20, CD19 and BAFF are now used to treat autoimmune diseases, including systemic lupus erythematosus and multiple sclerosis. The use of BCDTs in autoimmune disease has led to some surprises. For example, although antibody-secreting plasma cells are thought to have a negative pathogenic role in autoimmune disease, BCDT, even when it controls the disease, has limited impact on these cells and on antibody levels. In this Review, we update our understanding of B cell biology, review the results of clinical trials using BCDT in autoimmune indications, discuss hypotheses for the mechanism of action of BCDT and speculate on evolving strategies for targeting B cells beyond depletion.Keywords
This publication has 298 references indexed in Scilit:
- Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactionsNature, 2012
- TLR1/2, TLR7, and TLR9 Signals Directly Activate Human Peripheral Blood Naive and Memory B Cell Subsets to Produce Cytokines, Chemokines, and Hematopoietic Growth FactorsJournal of Clinical Immunology, 2010
- B‐cell activation influences T‐cell polarization and outcome of anti‐CD20 B‐cell depletion in central nervous system autoimmunityAnnals of Neurology, 2010
- Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple SclerosisArchives of Neurology, 2010
- Guidance of B Cells by the Orphan G Protein-Coupled Receptor EBI2 Shapes Humoral Immune ResponsesImmunity, 2009
- Cytokine-Producing Effector B Cells Regulate Type 2 Immunity to H. polygyrusImmunity, 2009
- Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodiesThe Lancet Neurology, 2008
- A Regulatory B Cell Subset with a Unique CD1dhiCD5+ Phenotype Controls T Cell-Dependent Inflammatory ResponsesImmunity, 2008
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004